REFERENCIAS BIBLIOGRÁFICAS
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Huang C. et al. Clinical features of patients infected with
2019 novel coronavirus in Wuhan, China. Lancet.
2020;395(10223):497–506. DOI:
10.1016/S0140-6736(20)30183-5.
Gupta A. et al. Extrapulmonary manifestations of
COVID-19. Nat Med. 2020;26(7):1017-1032. DOI:
10.1038/s41591-020-0968-3.
Jia HP. et al. ACE2 receptor expression and severe acute
respiratory syndrome coronavirus infection depend on
differentiation of human airway epithelia. J Virol.
2005;79(23):14614-14621. DOI:
10.1128/JVI.79.23.14614-14621.2005.
Dalan R. et al. The ACE-2 in COVID-19: Foe or Friend?.
Horm Metab Res. 2020;52(5):257-263. DOI:
10.1055/a-1155-0501.
Hamming I. et al. Tissue distribution of ACE2 protein, the
functional receptor for SARS coronavirus. A first step in
understanding SARS pathogenesis. J Pathol.
2004;203(2):631-637. DOI: 10.1002/path.1570.
Hirano T and Murakami M. COVID-19: A New Virus, but a
Familiar Receptor and Cytokine Release Syndrome.
Immunity. 2020;52(5):731-733. DOI:
10.1016/j.immuni.2020.04.003.
Hoffmann M. et al. SARS-CoV-2 Cell Entry Depends on
ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven
Protease Inhibitor. Cell. 2020;181(2):271-280.e8. DOI:
10.1016/j.cell.2020.02.052.
Padmanabhan P. et al. Targeting TMPRSS2 and Cathepsin
B/L Together May Be Synergistic Against SARS-CoV-2
Infection. PLoS Comput Biol. 2020 Dec 8;16(12):e1008461.
DOI: 10.1371/journal.pcbi.1008461
Pišlar A. et al. The role of cysteine peptidases in
coronavirus cell entry and replication: The therapeutic
potential of cathepsin inhibitors. PLoS Pathog.
2020;16(11):e1009013. DOI:10.1371/journal.ppat.1009013.
Pan L. et al. Clinical Characteristics of COVID-19 Patients
With Digestive Symptoms in Hubei, China: A Descriptive,
Cross-Sectional, Multicenter Study. Am J Gastroenterol.
2020;115(5):766-773. DOI:
10.14309/ajg.0000000000000620.
Zhang C. et al. Liver injury in COVID-19: management and
challenges. Lancet Gastroenterol Hepatol.
2020;5(5):428-430. DOI: 10.1016/S2468-1253(20)30057-1.
Wilson MP. et al. Potential implications of novel
coronavirus disease (COVID-19) related gastrointestinal
symptoms for abdominal imaging. Radiography (Lond).
2020;26(3):274. DOI: 10.1016/j.radi.2020.04.016.
Dioscoridi L. Pancreas and coronavirus disease-2019.
Pancreas Open J. 2020; 4(1): 1-2. DOI: 10.17140/POJ-4-111.
Olson MC. et al. RadioGraphics Update: Venous
Thrombosis and Hypercoagulability in the Abdomen and
Pelvis-Findings in COVID-19. Radiographics.
2020;40(5):E24-E28. DOI: 10.1148/rg.2020200119.
Revzin MV. et al. Multisystem Imaging Manifestations of
COVID-19, Part 2: From Cardiac Complications to Pediatric
Manifestations. Radiographics. 2020;40(7):1866-1892. DOI:
10.1148/rg.2020200195.
Lui K. et al. Abdominal imaging findings in patients with
SARS-CoV-2 infection: a scoping review. Abdom Radiol
(NY). 2020;1-7. DOI: 10.1007/s00261-020-02739-5.
Harwood R. et al. Paediatric abdominal pain in the time of
COVID-19: a new diagnostic dilemma. J. of Surg Case
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
Report. 2020(9): rjaa337. DOI: 10.1093/jscr/rjaa337.
18. Bhayana R. et al. Abdominal Imaging Findings in
COVID-19: Preliminary Observations. Radiology.
2020;297(1):E207-E215. DOI: 10.1148/radiol.2020201908.
Abdelmohsen MA. et al. Diagnostic value of abdominal
sonography in confirmed COVID-19 intensive care
patients. The Egyptian Journal of Radiology and Nuclear
Medicine. 2020;51(1):198. DOI:
10.1186/s43055-020-00317-9.
Parry AH. et al. Acute Mesenteric Ischemia in Severe
Coronavirus-19 (COVID-19): Possible Mechanisms and
Diagnostic Pathway. Acad Radiol. 2020;27(8):1190. DOI:
10.1016/j.acra.2020.05.016.
Revzin MV. et al. Multisystem Imaging Manifestations of
COVID-19, Part 1: Viral Pathogenesis and Pulmonary and
Vascular System Complications. Radiographics.
2020;40(6):1574-1599. DOI: 10.1148/rg.2020200149.
Alqahtani SA. and Schattenberg JM. Liver injury in
COVID-19: The current evidence. United European
Gastroenterol J. 2020;8(5):509-519. DOI:
10.1177/2050640620924157.
Chai X. et al. Specific ACE2 Expression in Cholangiocytes
May Cause Liver Damage After 2019-nCoV Infection.
BioRxiv. 04 Feb 2020. DOI: 10.1101/2020.02.03.931766.
Li H. et al Coronavirus disease 2019 (COVID-19): current
status and future perspectives. Int J Antimicrob Agents.
2020;55(5):105951. DOI:
10.1016/j.ijantimicag.2020.105951.
Lei P. et al. Liver injury in patients with COVID-19: clinical
profiles, CT findings, the correlation of the severity with
liver injury. Hepatol Int. 2020;14(5):733-742. DOI:
10.1007/s12072-020-10087-1.
Medeiros AK. et al. Higher frequency of hepatic steatosis at
CT among COVID-19-positive patients. Abdom Radiol
(NY). 2020;45(9):2748-2754. DOI:
10.1007/s00261-020-02648-7.
Palomar-Lever A. et al. Hepatic steatosis as an
independent risk factor for severe disease in patients with
COVID-19: A computed tomography study. JGH Open.
2020 Aug 4:10.1002/jgh3.12395. DOI: 10.1002/jgh3.12395.
Low SW. et al. Gastric ischemia and portal vein thrombosis
in a COVID-19-infected patient. Endoscopy. 2020
Dec;52(12):E465-E466. DOI: 10.1055/a-1230-3357.
Liu F. et al. ACE2 Expression in Pancreas May Cause
Pancreatic Damage After SARS-CoV-2 Infection. Clin
Gastroenterol Hepatol. 2020;18(9):2128-2130.e2. DOI:
10.1016/j.cgh.2020.04.040.
Patnaik RNK. et al. Acute pancreatic injury induced by
COVID-19. IDCases. 2020;22:e00959. DOI:
10.1016/j.idcr.2020.e00959.
Kumaran NK. et al. Coronavirus disease-19 (COVID-19)
associated with acute necrotising pancreatitis (ANP). BMJ
Case Rep. 2020;13(9):e237903. DOI:
10.1136/bcr-2020-237903.
Szatmary P. et al. Emerging Phenotype of Severe Acute
Respiratory Syndrome-Coronavirus 2-associated
Pancreatitis. Gastroenterology. 2020;159(4):1551-1554.
DOI: 10.1053/j.gastro.2020.05.069.
Brikman S. et al. Acute pancreatitis in a 61-year-old man
with COVID-19. CMAJ. 2020;192(30):E858-E859. DOI:
10.1503/cmaj.201029.
Wang K. et al. Acute Pancreatitis as the Initial
ARTÍCULO ESPECIAL
31
Rev méd panacea 2022 Ene-Abr;11(1): 17-32
Ramírez Cotrina Cesar Augusto et al.